GlaxoSmithKline plc (LON:GSK) insider Emma Walmsley sold 66,159 shares of the stock in a transaction on Friday, February 15th. The stock was sold at an average price of GBX 1,585 ($20.71), for a total value of £1,048,620.15 ($1,370,207.96).

Emma Walmsley also recently made the following trade(s):

  • On Monday, February 18th, Emma Walmsley sold 9,053 shares of GlaxoSmithKline stock. The stock was sold at an average price of GBX 1,576 ($20.59), for a total value of £142,675.28 ($186,430.52).
  • On Thursday, January 10th, Emma Walmsley bought 8 shares of GlaxoSmithKline stock. The shares were bought at an average cost of GBX 1,524 ($19.91) per share, for a total transaction of £121.92 ($159.31).
  • On Tuesday, December 11th, Emma Walmsley bought 8 shares of GlaxoSmithKline stock. The shares were bought at an average cost of GBX 1,494 ($19.52) per share, for a total transaction of £119.52 ($156.17).

GlaxoSmithKline stock opened at GBX 1,551 ($20.27) on Thursday. GlaxoSmithKline plc has a 12 month low of GBX 1,235.20 ($16.14) and a 12 month high of GBX 1,724.50 ($22.53).

The company also recently announced a dividend, which will be paid on Thursday, April 11th. Shareholders of record on Thursday, February 21st will be given a GBX 23 ($0.30) dividend. The ex-dividend date of this dividend is Thursday, February 21st. This is an increase from GlaxoSmithKline’s previous dividend of $19.00. This represents a yield of 1.49%.

Several analysts have recently issued reports on GSK shares. Shore Capital lowered GlaxoSmithKline to a “hold” rating in a report on Friday, January 18th. HSBC set a GBX 1,820 ($23.78) price objective on GlaxoSmithKline and gave the company a “buy” rating in a research note on Friday, January 25th. Liberum Capital reaffirmed a “hold” rating and issued a GBX 1,510 ($19.73) price objective on shares of GlaxoSmithKline in a research note on Monday, January 21st. Deutsche Bank set a GBX 1,520 ($19.86) price objective on GlaxoSmithKline and gave the company a “neutral” rating in a research note on Thursday, December 20th. Finally, Barclays reaffirmed an “equal weight” rating on shares of GlaxoSmithKline in a research note on Tuesday, January 15th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and six have given a buy rating to the company. GlaxoSmithKline presently has a consensus rating of “Hold” and a consensus target price of GBX 1,520.93 ($19.87).

TRADEMARK VIOLATION WARNING: “Insider Selling: GlaxoSmithKline plc (GSK) Insider Sells 66,159 Shares of Stock” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2019/02/21/insider-selling-glaxosmithkline-plc-gsk-insider-sells-66159-shares-of-stock.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

See Also: Relative Strength Index

Insider Buying and Selling by Quarter for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.